DePuy Synthes, part of the Johnson & Johnson Medical Device Companies, announced clinical results associated with its Corail hip system femoral stems. The results were announced at the World Arthroplasty Congress in Rome.
According to a press release from DePuy Synthes, results from the Bespoke Implant Report — an independently performed analysis of National Joint Registry for England, Wales, Northern Ireland and the Isle of Man (NJR) data — showed both the collarless and collared versions of the Corail cementless stem performed “in line with industry expectations.” The Corail standard collared stem correlated with a 29% lower revision risk compared with other cementless stems in the NJR.
According to the release, the Corail standard collarless femoral stem had an overall revision rate of 4% at 10 years, which was statistically comparable to other uncemented stems in the NJR. The standard collared femoral stem had a 2.7% revision rate overall, which was statistically significantly lower vs. other uncemented stems in the NJR. The Corail standard collared femoral stem compared to other uncemented stems in the NJR also had significantly lower than expected revision rates due to pain, dislocation, aseptic loosening and periprosthetic fracture.
“While the entire Corail portfolio has a long and successful clinical heritage, this latest information is significant as it reinforces that using a proven, robust construct design with a strong supportive evidence base may help reduce the revision risk for patients and the associated cost burden to health care systems,” Torbjorn Sköld, vice president for DePuy Synthes Europe, the Middle East and Asia Joint Reconstruction, said in the release.